According to CoinMeta, Fengyuan Pharmaceutical announced that the company has received the "Drug Registration Certificate" for tirofiban hydrochloride concentrated solution for injection, issued by the National Medical Products Administration. This drug is used for adult patients with non-ST segment elevation acute coronary syndrome to prevent early myocardial infarction, as well as for patients with acute myocardial infarction who plan to undergo direct PCI, in order to reduce the occurrence of major cardiovascular events.